ストックスクリーナーアプリを入手
6.54
2.03%
0.13
前日終値:
$6.41
開ける：
$6.46
24時間の取引高:
69,087
Relative Volume:
0.27
時価総額：
$143.13M
収益：
-
当期純損益:
$-69.87M
株価収益率:
-2.0381
EPS:
-3.2089
ネットキャッシュフロー:
$-61.75M
1週間 パフォーマンス:
-17.22%
1か月 パフォーマンス:
+4.47%
6か月 パフォーマンス:
-45.95%
1年 パフォーマンス:
-41.92%
1日の値動き範囲:
$6.175
$6.8152
1週間の範囲:
$6.175
$7.76
52週間の値動き範囲:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
名前
Aardvark Therapeutics Inc
セクター
電話
(858) 225-7696
住所
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
6.54 | 143.78M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | ダウングレード | Stifel | Buy → Hold |
| 2026-01-28 | 開始されました | B. Riley Securities | Buy |
| 2025-12-23 | 開始されました | Oppenheimer | Outperform |
| 2025-12-12 | 開始されました | William Blair | Outperform |
| 2025-12-03 | 開始されました | Raymond James | Strong Buy |
| 2025-11-07 | 開始されました | BTIG Research | Buy |
| 2025-09-29 | 開始されました | Stifel | Buy |
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 開始されました | BofA Securities | Buy |
| 2025-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 開始されました | Morgan Stanley | Overweight |
| 2025-03-10 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aardvark Therapeutics Inc (AARD) 最新ニュース
Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen - MarketBeat
Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action - lincolnjournal.com
Aardvark Therapeutics Company Profile & Introduction - Moomoo
AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges - TipRanks
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Morgan Stanley Maintains Aardvark Therapeutics(AARD.US) With Sell Rating, Maintains Target Price $3 - Moomoo
Why is Aardvark Therapeutics stock surging today? By Investing.com - Investing.com Canada
Why is Aardvark Therapeutics stock surging today? - Investing.com
Aardvark Therapeutics Q2 EPS of $(0.66) beats $(0.91) estimate - scanx.trade
Form 8K Aardvark Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Aardvark Therapeutics (AARD) faces ARD-101 clinical hold but retains $73.9M cash - Stock Titan
Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Aardvark Therapeut reports Q2 2026 results — $73.9M cash; net loss $14.4M - TradingView
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Aardvark Therapeutics, Inc. Q2 2026: Net loss $14.4M, EPS $(0.66) — 10-Q Summary - TradingView
Aardvark Reports $14.4 Million Q2 Net Loss as ARD-101 Hold Continues - quiverquant.com
AARD: Q2 2026 net loss was $14.4M; cash reserves support operations into late 2027 - TradingView
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction - TradingView
Aardvark Therapeutics Reports Q2 2026 Results, Updates ARD-101 PWS Program and FDA Discussions - quiverquant.com
Aardvark to Assess Unblinded Prader-Willi Trial Data in Q3 2026 - Stock Titan
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a shareEarnings Preview - TradingView
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
Aardvark Therapeutics (AARD) Surges 5.8% as Biotech Names Draw Fresh AttentionHead and Shoulders - dars.gov.et
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Hold" by Brokerages - MarketBeat
Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% LowerHagens Berman - PR Newswire
Aardvark Therapeutics Inc (AARD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aardvark Therapeutics Inc (AARD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aardvark Therapeutics Inc (AARD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aardvark Therapeutics Inc (AARD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aardvark Therapeutics Inc (AARD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aardvark Therapeutics Inc (AARD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AARD|Aardvark Therapeutics Inc|Price:6.437|Chg%:+0.117 - TradingKey
TradingKey - TradingKey
Aardvark Therapeutics Inc (AARD) Balance Sheet - TradingKey
Aardvark Therapeutics Inc (AARD) Income Statement - tradingkey.com
Aardvark Therapeutics Inc (AARD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AARD|Aardvark Therapeutics Inc|Price:6.680|Chg%:+0.360 - TradingKey
US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead - Streetwise Reports
Aardvark Therapeutics, Inc. Revenue Breakdown – NASDAQ:AARD - TradingView
Aardvark Therapeutics (AARD) Slips 1.25% as Stock Tests Key Support LevelsKAMA Signal - dars.gov.et
What is HC Wainwright's Forecast for AARD FY2027 Earnings? - MarketBeat
AARD Reiterates by HC Wainwright & Co. -- Price Target Announced at $6.00 - GuruFocus
H.C. Wainwright Maintains Aardvark Therapeutics(AARD.US) With Hold Rating, Announces Target Price $6 - Moomoo
Ram Selvaraju Maintains Hold on Aardvark, Assigns $6 Valuation Amid FDA Clinical Hold on ARD-101 and Lowered Approval Odds - TipRanks
Aardvark Therapeutics (AARD) Revenue BreakdownMain Composition - Moomoo
Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News - Moomoo
Morgan Stanley downgrades Aardvark Therapeutics (AARD) - MSN
What's going on with Aardvark Therapeutics stock on Wednesday? - MSN
[DEF 14A] Aardvark Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Aardvark Therapeutics, Inc. SEC Filing (Jul 10, 2026) - Stock Titan
Aardvark Therapeutics Inc (AARD) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):